Tag:

Eisai

Latest Headlines

Latest Headlines

When is 5 years not 5 years? When it's the FDA counting, Eisai claims

What makes a 5-year exclusivity period? Under U.S. law, it's the 5 years after FDA starts the clock ticking. Eisai has no qualms about that. But the Japanese drugmaker says the agency started that clock much too soon for two of its products--and it's suing the FDA to change that.

Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU

Still suffering from the loss of patent protection on its big Alzheimer's drug Aricept, Japan's Eisai said today that the company had fired off a pair of applications for its new cancer drug to U.S. as well as European regulators.

UPDATED: Orexigen's weight-loss med sets up Takeda vs. Eisai marketing showdown--eventually

Orexigen Therapeutics is on the verge of FDA approval for its obesity drug, after several long years of delay and frustration. But despite its late-to-the-party status--it's the third weight-loss pill in a new generation of treatments--it may end up winning the popularity contest.

With DTC on a roll, Eisai plots another 200-rep boost to Belviq sales team

The Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team.

Fresh off a TV ad launch, Eisai plots another 200-rep add to Belviq sales force

Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team. On top of a new television ad push begun last month, the sales-force expansion is a one-two punch aimed at keeping prescription trends on the upswing.

Biogen Idec buys into Eisai's BACE camp on Alzheimer's as drug race heats up

The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits. 

Eisai's revved-up Belviq marketing starting to pay off, analysts say

When it comes to addressing the market, pharma has three P's, according to Eisai's Michael O'Brien: physician, payer and patient. And as VP of specialty marketing, O'Brien is looking to hit each of them in promoting the recently launched weight-loss drug Belviq.

Eisai readies applications for thyroid cancer drug after PhIII success

Eisai has begun to lay the groundwork for a slate of marketing applications in the U.S., Europe and Japan for a new thyroid cancer therapy after wrapping up a successful Phase III study of the drug, which is also noteworthy for relying on an innovative collaborative approach to the development process

Eisai to cut R&D, even as it boosts its sales operation

Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world.

UPDATED: Eisai brings ax down on U.S. R&D op, chops 130 staffers worldwide

Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.